Intercept Pharmaceuticals Stock Current Valuation
| ICPTDelisted Stock | USD 10.31 0.16 1.53% |
Valuation analysis of Intercept Pharmaceuticals helps investors to measure Intercept Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Intercept Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Intercept Pharmaceuticals is based on 3 months time horizon. Increasing Intercept Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Intercept Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 10.31, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.31 | Real 10.01 | Hype 10.31 | Naive 11.43 |
The intrinsic value of Intercept Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Intercept Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Intercept Pharmaceuticals helps investors to forecast how Intercept stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Intercept Pharmaceuticals more accurately as focusing exclusively on Intercept Pharmaceuticals' fundamentals will not take into account other important factors: Intercept Pharmaceuticals Company Current Valuation Analysis
Intercept Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Intercept Pharmaceuticals Current Valuation | 695.84 M |
Most of Intercept Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intercept Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Intercept Pharmaceuticals has a Current Valuation of 695.84 M. This is 95.16% lower than that of the Biotechnology sector and 85.02% lower than that of the Health Care industry. The current valuation for all United States stocks is 95.81% higher than that of the company.
Intercept Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intercept Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intercept Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Intercept Pharmaceuticals by comparing valuation metrics of similar companies.Intercept Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Intercept Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 | |||
| Profit Margin | (0.19) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 695.84 M | |||
| Shares Outstanding | 41.81 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 81.30 % | |||
| Number Of Shares Shorted | 10.19 M | |||
| Price To Earning | (3.88) X | |||
| Price To Book | 44.19 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 285.71 M | |||
| Gross Profit | 284.73 M | |||
| EBITDA | (61.7 M) | |||
| Net Income | (174.86 M) | |||
| Cash And Equivalents | 404.78 M | |||
| Cash Per Share | 13.58 X | |||
| Total Debt | 332.67 M | |||
| Debt To Equity | 411.20 % | |||
| Current Ratio | 3.22 X | |||
| Book Value Per Share | 1.72 X | |||
| Cash Flow From Operations | (26.78 M) | |||
| Short Ratio | 2.64 X | |||
| Earnings Per Share | (4.26) X | |||
| Price To Earnings To Growth | (0.69) X | |||
| Target Price | 19.0 | |||
| Number Of Employees | 341 | |||
| Beta | 0.88 | |||
| Market Capitalization | 794.36 M | |||
| Total Asset | 553.71 M | |||
| Retained Earnings | (2.14 B) | |||
| Working Capital | 310.05 M | |||
| Current Asset | 641.69 M | |||
| Current Liabilities | 47.37 M | |||
| Z Score | -3.15 | |||
| Net Asset | 553.71 M |
About Intercept Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intercept Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intercept Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intercept Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |